Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TG02 in Recurrent High-Grade Glioma
NCT03904628Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Mar 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zotiraciclib in glioblastoma (GBM) and anaplastic astrocytoma (AA) (3 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoints: Dose limiting toxicity at 28 days and Maximal tolerable dose at 28 days. Status: unknown.
02
Drugs
zotiraciclib
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT03904628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904628.